NASDAQ-NMS:SNY

Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities

Retrieved on: 
Thursday, November 2, 2023
RSV, Historically black colleges and universities, Social media, Black, Sickle cell disease, Physician, PASD, Equity, Navigation, Trust, Quality of life, Vaccination, Caregiver, Clinical trial, Partnership, African Americans, Nursing, Patient, Diagnosis, Coagulopathy, MS, Birth control, Vaccine, BMT, University

KO Flu and Covid will engage and communicate with seniors about influenza risks and the benefits of vaccination by utilizing boxing events in historically disadvantaged communities.

Key Points: 
  • KO Flu and Covid will engage and communicate with seniors about influenza risks and the benefits of vaccination by utilizing boxing events in historically disadvantaged communities.
  • This service will assist patients and caregivers by clarifying treatment options, providing biomarker testing education, and identifying clinical trial options.
  • Transplant Equity and Awareness for Sickle Cell Disease will address low stem cell donation and the underutilization of Bone Marrow Transplant (BMT) treatment.
  • This multi-organization partnership strives to lead an educational awareness program targeting Black and Hispanic communities in the US.

Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.

Retrieved on: 
Wednesday, November 1, 2023
Patient, Fitness, Child, Social media, Education, Pledge, Family, Hope, Pancreas, Autoantibody, Diabetes, Times Square, Learning, Disease, Caregiver, Risk, Robin, Go for Your Life (fitness program), Autoimmune disease, Sanofi, Movement, Diagnosis, Entertainment, Pharmaceutical industry

Had we detected my child's type 1 diabetes before their diagnosis it could have given us valuable time to prepare.

Key Points: 
  • Had we detected my child's type 1 diabetes before their diagnosis it could have given us valuable time to prepare.
  • We have been advocating for awareness around type 1 diabetes for nearly as many years as she has been living with diabetes.
  • By using personal stories, these celebrities aim to share the importance of screening, education and preparation for type 1 diabetes.
  • Sanofi encourages people interested in learning more about screening or type 1 diabetes to speak to their doctor.

Stagwell's (STGW) The Harris Poll Unveils First-of-its-kind Global Hemophilia Survey on the Daily Challenges for Patients, Caregivers, and Providers

Retrieved on: 
Tuesday, October 10, 2023
Haemophilia, Probability, Stagwell, MBA, Communication, Anxiety, Human, Caregiver, MPH, Medical Affairs Bureau, Health, Rare, Disease, Patient, Data, Research, Depression, Friends, The Harris Poll, Child, Hematology, Life, Face, Nursing, Pharmaceutical industry, Residential care, MD, Sanofi

NEW YORK, Oct. 10, 2023 /PRNewswire/ -- The Harris Poll, a Stagwell (NASDAQ: STGW) agency, announced today the findings from a first-of-its-kind global hemophilia survey – 'Hemophilia Life Stages and Changes Global Survey' – sponsored by Sanofi. The findings deliver critical insights from patients, caregivers, and hematologists on challenges they face in their daily lives as they live or care for those with hemophilia across important life stages. The Harris Poll and Sanofi conducted the survey of more than 2,700 participants across four continents and 11 countries to gain a greater understanding of the current state of hemophilia care globally, the evolving needs of this community over their lifetime, and the areas that require improvement. 

Key Points: 
  • NEW YORK, Oct. 10, 2023 /PRNewswire/ -- The Harris Poll , a Stagwell (NASDAQ: STGW) agency, announced today the findings from a first-of-its-kind global hemophilia survey – 'Hemophilia Life Stages and Changes Global Survey' – sponsored by Sanofi.
  • The findings deliver critical insights from patients, caregivers, and hematologists on challenges they face in their daily lives as they live or care for those with hemophilia across important life stages.
  • The goal is to drive action and dialogue that leads to improved care for people with hemophilia.
  • The results of the survey provide valuable insights for caregivers, patients living with hemophilia, healthcare professionals, policymakers, and patient organizations worldwide.

Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu

Retrieved on: 
Wednesday, September 13, 2023
Vaccine, Asthma, Ice-T, Diabetes, Vaccination, Public, Stroke, Influenza vaccine, Hope, American Society of Consultant Pharmacists, ASCP, CDC, Pharmacist, Risk, Ageing, United, Society, Pneumonia, Season, Sanofi

The trailer taps into suspenseful movie tropes to educate older adults, particularly those with chronic health conditions, about the risks associated with the flu.

Key Points: 
  • The trailer taps into suspenseful movie tropes to educate older adults, particularly those with chronic health conditions, about the risks associated with the flu.
  • The Season serves as a powerful reminder about the importance of higher-dose flu vaccines to help protect more vulnerable populations from the flu and its related complications.
  • "The flu can be a serious public health threat and lead to complications such as heart attack, stroke, and pneumonia.
  • You can also see more content from The Season here and share your support by using #PrepareForTheSeason on your social channels.

Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact

Retrieved on: 
Tuesday, July 25, 2023
Certification, Sanofi, B Lab, B Corporation (certification), Recycling

BRIDGEWATER, N.J., July 25, 2023 /PRNewswire/ -- After making strides in environmental sustainability and social impact commitments, Sanofi Consumer Healthcare North America is pleased to announce it has earned B Corp Certification.

Key Points: 
  • BRIDGEWATER, N.J., July 25, 2023 /PRNewswire/ -- After making strides in environmental sustainability and social impact commitments, Sanofi Consumer Healthcare North America is pleased to announce it has earned B Corp Certification.
  • Sanofi Consumer Healthcare North America has products in nearly 54 million households in the U.S and Canada, including Allegra®, Icy Hot®, Dulcolax® and Unisom®.
  • B Lab measures a company's entire social and environmental impact and attaining B Corp Certification means a company meets high standards of social and environmental performance, accountability, and transparency.
  • Sanofi Consumer Healthcare North America earned B Corp Certification because of its continued commitment to social impact and sustainability, including:

Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi

Retrieved on: 
Thursday, May 18, 2023
Government, SNY, Federal Circuit Court, Research, Patient, Patent, Regeneron Pharmaceuticals, Judge, Supreme court, Sanofi, Amgen

Decision unanimously affirms the United States Federal Circuit Court's opinion that Amgen's asserted U.S. PCSK9 patent claims are invalid

Key Points: 
  • Decision unanimously affirms the United States Federal Circuit Court's opinion that Amgen's asserted U.S. PCSK9 patent claims are invalid
    BRIDGEWATER, N.J., May 18, 2023 /PRNewswire/ -- Sanofi (NASDAQ: SNY) is pleased with the United States Supreme Court's ruling in Amgen v. Sanofi et.
  • The decision unanimously affirms the United States Federal Circuit Court's opinion that is favorable to Sanofi and Regeneron.
  • This ruling reinforces our longstanding belief that Amgen's asserted patent claims are invalid and represents an unequivocal win for America's innovation economy, its scientists, and researchers.
  • We thank the Justices and the many groups, individuals and the U.S. government who supported our defense of scientific innovation.

Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare

Retrieved on: 
Wednesday, January 18, 2023
Student, Trust, Education, Public health, Nursing, Empathy, BRC, Public, Harvard University, Hope, Woman, Policy, Health, Patient, Research, Bias, Faculty, Inclusion, Disability, Health insurance, Medicine, Pharmaceutical industry, Sanofi

PARIS, Jan. 18, 2023 /PRNewswire/ -- Sanofi announces at the 53rd Annual Meeting of the World Economic Forum in Davos the launch of the Sanofi NextGen Scholarship, its first global higher education scholarship program for people from numerous communities underrepresented in healthcare professions.

Key Points: 
  • PARIS, Jan. 18, 2023 /PRNewswire/ -- Sanofi announces at the 53rd Annual Meeting of the World Economic Forum in Davos the launch of the Sanofi NextGen Scholarship, its first global higher education scholarship program for people from numerous communities underrepresented in healthcare professions.
  • The launch of the Sanofi NextGen Scholarship program follows the results of a global survey of underrepresented groups' trust in healthcare, the first of its kind.
  • Sponsored by Sanofi, the survey showed diminished trust in healthcare systems among underrepresented communities, with nearly 75% of people from underrepresented populations saying they have suffered trust-damaging healthcare experiences.
  • The Sanofi NextGen Scholarship program is part of 'A Million Conversations', Sanofi's broader €50 million initiative that aims to create greater trust between underrepresented communities and healthcare stakeholders by 2030.

Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes

Retrieved on: 
Thursday, October 6, 2022
SAN, AMF, Risk, Medicine, SEC, Form 20-F, Commercialization, Science, SNY, Regulation of tobacco by the U.S. Food and Drug Administration, NASDAQ, U.S. FDA, Research, Annual report, Private Securities Litigation Reform Act, R, Autoantibody, Food, Pharmacovigilance, Marketing, Safety, Social responsibility, Intellectual property, Insulin, Forward-looking statement, Death, FDA, COVID-19, Pancreas, Regulation, Pharmaceutical industry, Medical device, Risk management, T1D, Teplizumab, Sanofi

If approved by the U.S. Food and Drug Administration (FDA), teplizumab would be the first-ever disease-modifying therapy in T1D.

Key Points: 
  • If approved by the U.S. Food and Drug Administration (FDA), teplizumab would be the first-ever disease-modifying therapy in T1D.
  • If approved, Sanofi US will leverage our existing world-class capabilities in diabetes care to enhance efforts in both patient and healthcare provider access.
  • We are prepared to tap into all of our internal expertise to support the successful launch of this innovative therapy."
  • Dependent on a positive decision from the FDA, Provention Bio will contract Sanofi US customer-facing field teams.

Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis

Retrieved on: 
Wednesday, September 28, 2022

TARRYTOWN, N.Y. and PARIS, Sept. 28, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with prurigo nodularis. With this approval, Dupixent becomes the first and only medicine specifically indicated to treat prurigo nodularis in the U.S. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is one of the highest among inflammatory skin diseases. The FDA evaluated the Dupixent application for prurigo nodularis under Priority Review, which is granted to therapies that have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions.

Key Points: 
  • You should not receive a "live vaccine" right before and during treatment with DUPIXENT.
  • A pregnancy registry for women who take DUPIXENT during pregnancy collects information about the health of you and your baby.
  • This may cause other symptoms that were controlled by the corticosteroid medicine or other asthma medicine to come back.
  • It is not known if DUPIXENT is safe and effective in children with prurigo nodularis under 18 years of age.

Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis

Retrieved on: 
Thursday, September 8, 2022

TARRYTOWN, N.Y. and PARIS, Sept. 8, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented detailed positive results from the second of two Phase 3 trials (PRIME) evaluating Dupixent® (dupilumab) in adults with uncontrolled prurigo nodularis in a late-breaking session at the European Academy of Dermatology and Venereology (EADV) 2022 Congress. These data, which were consistent with the detailed data from the first Phase 3 trial (PRIME2) in prurigo nodularis, show Dupixent significantly reduced itch and skin lesions at 24 weeks.

Key Points: 
  • A pregnancy registry for women who take DUPIXENT during pregnancy collects information about the health of you and your baby.
  • Do not change or stop your corticosteroid medicine or other asthma medicine without talking to your healthcare provider.
  • This may cause other symptoms that were controlled by the corticosteroid medicine or other asthma medicine to come back.
  • Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized.